CDSCO streamlines exports for approved recombinant DNA drugs under new brands

The Central Drugs Standards Organisation has introduced a streamlined approval pathway for recombinant DNA drugs seeking export clearance under alternative brand names, provided the formulations have already received regulatory approval for domestic sale in India.

Under the new framework, manufacturers no longer need to obtain a separate export NOC for these approved biologics when they are marketed internationally under different brand identities. This measure represents a significant reduction in bureaucratic procedures for the biologics export sector, which has increasingly sought regulatory efficiency to compete in global markets.

The exemption applies specifically to recombinant DNA pharmaceuticals that have undergone the CDSCO's rigorous domestic approval process. Manufacturers utilising different brand names for overseas distribution—a common industry practice due to varying regulatory and commercial requirements across countries—can now proceed with exports more expeditiously.

Industry observers suggest the regulatory change will particularly benefit mid-sized and emerging biologics manufacturers that typically face resource constraints in navigating multiple approval pathways. By reducing redundant documentation requirements, the CDSCO has aimed to support India's growing biopharmaceutical export capabilities without compromising safety or quality standards.

The move aligns with broader government initiatives to enhance India's position in the global biologics market, where recombinant DNA drugs represent an increasingly significant segment of pharmaceutical exports from the country.